Table 1 Characteristics of the tight control studies
StudyInterventions/groupsnMedication at the startFrequency of assessmentInclusion criteriaDisease duration
FIN-RACoCombination therapy*Mono therapy9798SSZ, MTX, HCQ, prednSSZ ± predn3 months (variable)3/6 months (clinical decision/variable)ARA criteria RA, 18–65 yr,symptoms <2 yr, active disease ⩾3 SJ and 3 of: ⩾28 mm/h ESR or ⩾19 mg/l CRP, ⩾29 min/ms, >5 SJ or >10 TJ<2 yr
TICORAIntensive management*55DMARD, i.a. steroid1 month (DAS)18–75 yr, disease duration<5 yr
Routine management55DMARD mono3 months (clinical decision)<5 yr, active disease (DAS>2.4)
BeStSequential mono therapy*126MTX3 months (DAS44)ACR criteria RA, ⩾18 yr,⩽2 yr
Step-up combination therapy*121MTX3 months (DAS44)disease duration ⩽2 yr, active
Initial combination therapy + h.d. predn*Initial combination therapy + infliximab*133128MTX, SSZ, prednMTX, infliximab3 months (DAS44)3 months (DAS44)disease: ⩾6 of 66 SJ, ⩾6 of 68TJ, ⩾28 mm/h ESR, ⩾20 mmVAS global health
CAMERAIntensive strategy group*151MTX1 month (computer decision program)ACR criteria RA, >16 yr, earlyRA (<1 yr)<1 yr
Conventional strategy group148MTX3 months (clinical decision)
  • *Based on tight control treatment.

  • ACR criteria RA, American College of Rheumatism criteria for rheumatoid arthritis; ARA criteria RA, American Rheumatism Association criteria for rheumatoid arthritis; BeSt, Behandel Strategieën; CAMERA, Computer Assisted Management of Early Rheumatoid Arthritis; CRP, C-reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; HCQ, hydroxychloroquine; h.d., high-dose; i.a., intra-articular; ms, morning stiffness; MTX, methotrexate; predn, prednisone; SJ, swollen joints; SSZ, sulfasalazine; TICORA, Tight Control of Rheumatoid Arthritis; TJ, tender joints; VAS, visual analogue scale; yr, year(s).